On Sunday, Oct 26 2025, Medtronic plc announced the final three‑year results of its SPYRAL HTN‑ON MED randomized, sham‑controlled trial, demonstrating that patients who underwent renal denervation (RDN) with the Symplicity Spyral system experienced significantly greater reductions in both 24‑hour ambulatory systolic blood pressure (ABPM) and office‑based systolic blood pressure (OSBP) compared with sham controls.
The study enrolled 206 RDN patients and 131 sham patients. Across the three‑year follow‑up, the RDN group maintained durable blood‑pressure lowering effects, with no patients developing renal artery stenosis greater than 70%, underscoring the long‑term safety of the procedure. The data were presented as part of Featured Clinical Research at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference and were released via PR Newswire on the same day.
Medtronic noted that the Symplicity RDN system is approved for commercial use in nearly 80 countries worldwide, positioning the company to capitalize on a growing market for interventional hypertension therapies. The release provides the most comprehensive long‑term evidence to date for the Symplicity platform, reinforcing its clinical value and supporting future commercial expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.